Dhiraj Kumar

Dhiraj Kumar

Auto-generated profile, based on publicly available information

Dhiraj Kumar

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
Purpose: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; however, tools to quantify in situ drug exposure are few. We have investigated the potential of programmed death-ligand 1 (PD-L1) pharmacodynamics, quantified using PET, to inform on the tumor exposure of anti–PD-L1 (aPD-L1) therapeutics. Experimental Design: To noninvasively quantify PD-L1 levels, we first developed a novel peptide-based gallium-68–labeled binder, [68Ga]Ga-DK223, and evaluated its in vivo distribution, pharmacokinetics, and PD-L1 specificity in preclinical models of triple-negative breast cancer and urothelial carcinoma with variable PD-L1 expression. We then quantified baseline and accessible PD-L1 levels in tumors as a noninvasive pharmacodynamic measure to assess tumor exposure to two aPD-L1 antibodies (avelumab and durvalumab). Results: DK223 exhibited a KD of 1.01±0.83 nmol/L for PD-L1 and inhibited the PD-1:PD-L1 interaction in a dose-dependent manner. [68Ga]Ga-DK223 provides high-contrast PET images within 60 minutes of administration and detects PD-L1 in an expression-dependent manner in xenograft models. PD-L1 pharmacodynamics measured using [68Ga]Ga-DK223-PET revealed that avelumab and durvalumab had similar exposure early during therapy, but only durvalumab exhibited sustained exposure at the tumor. Conclusions: [68Ga]Ga-DK223 detected variable PD-L1 levels and exhibited salient features required for clinical translation. [68Ga]Ga-DK223-PET could be useful for quantifying total PD-L1 levels at baseline and accessible PD-L1 levels during therapy to understand drug exposure at the tumor, thus supporting its use for guiding and optimizing ICT.

25 November 2025
Verified
Other
Open access
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
Purpose:Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; however, tools to quantify in situ drug exposure are few. We have investigated the potential of programmed death-ligand 1 (PD-L1) pharmacodynamics, quantified using PET, to inform on the tumor exposure of anti–PD-L1 (aPD-L1) therapeutics.Experimental Design:To noninvasively quantify PD-L1 levels, we first developed a novel peptide-based gallium-68–labeled binder, [68Ga]Ga-DK223, and evaluated its in vivo distribution, pharmacokinetics, and PD-L1 specificity in preclinical models of triple-negative breast cancer and urothelial carcinoma with variable PD-L1 expression. We then quantified baseline and accessible PD-L1 levels in tumors as a noninvasive pharmacodynamic measure to assess tumor exposure to two aPD-L1 antibodies (avelumab and durvalumab).Results:DK223 exhibited a KD of 1.01±0.83 nmol/L for PD-L1 and inhibited the PD-1:PD-L1 interaction in a dose-dependent manner. [68Ga]Ga-DK223 provides high-contrast PET images within 60 minutes of administration and detects PD-L1 in an expression-dependent manner in xenograft models. PD-L1 pharmacodynamics measured using [68Ga]Ga-DK223-PET revealed that avelumab and durvalumab had similar exposure early during therapy, but only durvalumab exhibited sustained exposure at the tumor.Conclusions:[68Ga]Ga-DK223 detected variable PD-L1 levels and exhibited salient features required for clinical translation. [68Ga]Ga-DK223-PET could be useful for quantifying total PD-L1 levels at baseline and accessible PD-L1 levels during therapy to understand drug exposure at the tumor, thus supporting its use for guiding and optimizing ICT.

25 November 2025
Verified
Other
Open access
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
A, Comparison of hPD-L1 surface expression in different cancer cell lines with respective isotype.

1 April 2023
Verified
Other
Open access
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
A, Synthesis of DK223. B, RP-HPLC chromatogram of DK223.

1 April 2023
Verified
Other
Open access
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
A, Synthesis of DK223. B, RP-HPLC chromatogram of DK223.

1 April 2023
Verified
Other
Open access
AMAkhilesh Mishra
Akhilesh Mishra
DKDhiraj Kumar
Dhiraj Kumar
KGKULDEEP GUPTA
KULDEEP GUPTA
GLGabriela Lofland
Gabriela Lofland
ASAjay Kumar Sharma
Ajay Kumar Sharma
SNSridhar Nimmagadda
Sridhar Nimmagadda
A, Comparison of hPD-L1 surface expression in different cancer cell lines with respective isotype.